Venture Capital Investors

Hatteras Venture Partners

VC investing group Hatteras Venture Partners provides capital to promising high-tech companies.

Venture Investor Overview

Venture Investor
Hatteras Venture Partners
Status
Active
Investor Type
Venture Capital
Activity Level
105 transactions
Funds Raised
At least $439 million
Industry Focus
Biopharmaceutical
Healthcare IT
Medical Devices & Instruments
Software

Contact Information

Contact
Clay Thorp
Title
General Partner
Mailing Address
280 S. Mangum St. 350
Durham, NC 27701
USA
Phone
(919) 484-0730
Website
www.hatterasvp.com
Email Address
[email protected]

Background Information

Overview
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine.
Profile
Hatteras Venture Partners LinkedIn Company Profile
Social Media
Hatteras Venture Partners Company Twitter Account
Company News
Hatteras Venture Partners News
Facebook
Hatteras Venture Partners on Facebook
YouTube
Hatteras Venture Partners on YouTube
Last Transaction
6/15/2023

Transaction History

Our records indicate that Hatteras Venture Partners invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Ten63 Therapeutics
6/15/2023
$15,900,000
Myeloid Therapeutics
5/18/2023
$73,000,000
Ten63 Therapeutics
5/2/2023
$15,900,000
Aer Therapeutics
4/14/2023
$36,000,000
Mercy BioAnalytics
4/3/2023
$41,000,000
Cardiosense
12/9/2022
$15,100,000
Boomerang Medical
11/2/2022
$15,000,000
RapidPulse
9/13/2022
$10,500,000
Code Biotherapeutics
6/7/2022
$75,000,000
Wildflower Health
3/8/2022
$26,000,000
AN2 Therapeutics
1/7/2022
$80,000,000
Tune Therapeutics
12/3/2021
$40,000,000
Elligo Health Research
9/27/2021
$135,000,000
Vigil Neuroscience
8/19/2021
$90,000,000
RapidPulse
7/1/2021
$15,000,000
Veralox Therapeutics
6/18/2021
$16,600,000
Standard Bariatrics
6/2/2021
$35,000,000
Boston Immune Technologies and Therapeutics
3/18/2021
$10,000,000
StrideBio
3/17/2021
$81,500,000
Myeloid Therapeutics
1/7/2021
$50,000,000
Atsena Therapeutics
12/17/2020
$55,000,000
Vigil Neuroscience
12/9/2020
$50,000,000
Altis Biosystems
8/13/2020
$3,100,000
Shattuck Labs
6/16/2020
$118,000,000
AtaCor Medical
4/29/2020
$25,000,000
410 Medical
10/23/2019
$8,000,000
GrayBug Vision
8/21/2019
$80,000,000
Trefoil Therapeutics
7/17/2019
$28,000,000
Ribometrix
11/14/2018
$30,000,000
Kymera Therapeutics
11/14/2018
$65,000,000
Qpex Biopharma
10/23/2018
$33,000,000
PhaseBio Pharmaceuticals
9/6/2018
$34,000,000
ORIG3N
7/13/2018
Unknown
StrideBio
6/14/2018
$15,700,000
Elligo Health Research
3/21/2018
$16,000,000
Wildflower Health
3/8/2018
$8,000,000
NurseGrid
1/19/2018
$5,700,000
Qvella
12/5/2017
$20,000,000
PhaseBio Pharmaceuticals
11/30/2017
$15,600,000
Ribometrix
11/1/2017
$7,500,000
Rodin Therapeutics
9/20/2017
$27,000,000
ORIG3N
6/28/2017
$20,000,000
NeuroTronik
4/19/2017
$23,100,000
Boragen
3/3/2017
$10,000,000
Kollective
5/17/2016
$12,249,943
G1 Therapeutics
5/11/2016
$46,999,999
Bivarus
3/23/2016
$2,000,000
ORIG3N
12/9/2015
$12,500,000
PhaseBio Pharmaceuticals
9/30/2015
$99,900
Medfusion
9/2/2015
$3,000,000
Wildflower Health
6/29/2015
$5,000,000
NuSirt Biopharma
5/14/2015
$6,000,000
Spyryx Biosciences
5/8/2015
$18,000,000
Contego Medical
4/21/2015
$5,600,000
Innocrin
4/16/2015
$28,000,000
PhaseBio Pharmaceuticals
3/12/2015
$40,000,000
G1 Therapeutics
2/5/2015
$33,000,000
ORIG3N
2/5/2015
$3,100,000
Lysosomal Therapeutics
2/3/2015
$20,000,000
Clinipace
1/16/2015
$50,000,000
Viamet Pharmaceuticals
10/21/2014
$60,000,000
Clearside Biomedical
9/2/2014
$16,000,000
Clinverse
8/19/2014
$9,000,000
Lysosomal Therapeutics
5/13/2014
$4,800,000
Curoverse
12/19/2013
$1,500,000
Lineagen
12/18/2013
$3,500,000
Sideris Pharmaceuticals
10/23/2013
$32,000,000
G1 Therapeutics
10/16/2013
$12,500,000
GainSpan
6/27/2013
$19,000,000
NeuroTronik
6/14/2013
$13,100,000
Viamet Pharmaceuticals
12/31/2012
$3,000,100
HistoSonics
12/31/2012
$3,034,000
G1 Therapeutics
9/20/2012
$600,000
Coferon
7/17/2012
$12,000,000
KnowledgeTree
7/10/2012
$4,750,000
EvoApp
6/30/2012
$765,000
PhaseBio Pharmaceuticals
6/6/2012
$23,000,000
Clinverse
5/8/2012
$3,800,000
Kollective
2/29/2012
$5,100,000
SugarSync
2/29/2012
$15,000,000
GainSpan
12/5/2011
$18,000,000
Clinipace
9/27/2011
$15,000,000
Sailthru
9/20/2011
$8,000,000
Aggregate Knowledge
3/31/2011
$3,125,100
Univa
1/26/2011
$7,000,000
TetraLogic Pharmaceuticals
1/5/2011
$23,000,000
PhaseBio Pharmaceuticals
12/2/2010
$25,000,000
TetraLogic Pharmaceuticals
8/11/2010
$32,000,000
Anulex Technologies
6/4/2010
$18,260,000
Pathfinder Therapeutics
6/1/2010
$4,000,000
SiBEAM
3/9/2010
$36,500,000
CancerGuide Diagnostics
1/28/2010
$10,500,000
HistoSonics
1/4/2010
$11,000,000
Viamet Pharmaceuticals
7/7/2009
$18,000,000
ArtusLabs
3/31/2009
$55,000
Pathfinder Therapeutics
10/30/2008
$5,000,000
Viamet Pharmaceuticals
9/30/2008
$3,025,000
SpineWorks Medical
6/30/2008
$1,653,900
ArtusLabs
4/8/2008
$2,021,000
Clinipace
1/11/2008
$2,600,000
ArtusLabs
12/31/2007
$579,000
Viamet Pharmaceuticals
12/31/2007
$1,000,000
Advanced ICU Care
6/30/2007
$600,000
Respirics
6/20/2007
$2,500,000
Viamet Pharmaceuticals
6/7/2007
$4,000,000

 

Investor Contacts

Title
Name
Email & Social
General Partner
John Crumpler
  John Crumpler LinkedIn Profile  John Crumpler Twitter Account  John Crumpler News  John Crumpler on Facebook
General Partner
Robert Ingram
  Robert Ingram LinkedIn Profile  Robert Ingram Twitter Account  Robert Ingram News  Robert Ingram on Facebook
General Partner
Kenneth Lee
  Kenneth Lee LinkedIn Profile  Kenneth Lee Twitter Account  Kenneth Lee News  Kenneth Lee on Facebook
General Partner
Douglas Reed
  Douglas Reed LinkedIn Profile  Douglas Reed Twitter Account  Douglas Reed News  Douglas Reed on Facebook
General Partner
Christy Shaffer
  Christy Shaffer LinkedIn Profile  Christy Shaffer Twitter Account  Christy Shaffer News  Christy Shaffer on Facebook
General Partner
Clay Thorp
  Clay Thorp LinkedIn Profile  Clay Thorp Twitter Account  Clay Thorp News  Clay Thorp on Facebook

 

Funds

Our database includes the following fund closing(s) for Hatteras Venture Partners. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
HVP VI
4/12/2019
$94,000,000
Hatteras Venture Partners V
1/6/2017
$150,000,000
Hatteras Venture Partners IV
8/16/2011
$74,000,000
Hatteras Venture Partners III
9/30/2007
$83,000,000
HVP II
9/30/2004
$35,000,000
HVP I
6/30/2000
$3,000,000

 

Portfolio Companies

Hatteras Venture Partners has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
410 Medical
Advanced ICU Care
Aer Therapeutics
Aggregate Knowledge
Altis Biosystems
AN2 Therapeutics
Anulex Technologies
ArtusLabs
AtaCor Medical
Atsena Therapeutics
Bivarus
Boomerang Medical
Boragen
Boston Immune Technologies and Therapeutics
CancerGuide Diagnostics
Cardiosense
Clearside Biomedical
Clinipace
Clinverse
Code Biotherapeutics
Coferon
Contego Medical
Curoverse
Elligo Health Research
EvoApp
G1 Therapeutics
GainSpan
GrayBug Vision
HistoSonics
Innocrin
KnowledgeTree
Kollective
Kymera Therapeutics
Lineagen
Lysosomal Therapeutics
Medfusion
Mercy BioAnalytics
Myeloid Therapeutics
NeuroTronik
NurseGrid
NuSirt Biopharma
ORIG3N
Pathfinder Therapeutics
PhaseBio Pharmaceuticals
Qpex Biopharma
Qvella
RapidPulse
Respirics
Ribometrix
Rodin Therapeutics
Sailthru
Shattuck Labs
SiBEAM
Sideris Pharmaceuticals
SpineWorks Medical
Spyryx Biosciences
Standard Bariatrics
StrideBio
SugarSync
Ten63 Therapeutics
TetraLogic Pharmaceuticals
Trefoil Therapeutics
Tune Therapeutics
Univa
Veralox Therapeutics
Viamet Pharmaceuticals
Vigil Neuroscience
Wildflower Health

 

 

 

 

Browse more venture capital investors:

Hatcher+ | Hatzimemos Libby

 

Share this article

 

About Our VC & M&A Database

This VC firm profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.